SC Pharmaceuticals(002693)2025-01-17 13:00Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2024 to be in the range of a loss of 55 million to 80 million RMB, a decrease of 8.39% to 57.66% compared to the previous year[3]. - Total profit is projected to be a loss between 80 million and 110 million RMB, representing a decline of 9.64% to 50.75% year-over-year[3]. - Revenue is anticipated to be between 150 million and 190 million RMB, down from 235.93 million RMB in the same period last year[4]. - The company expects a significant increase in the loss of net profit after deducting non-recurring gains and losses, estimated between 58.37 million and 83.37 million RMB, compared to a loss of 24.14 million RMB last year[3]. Reasons for Profit Decline - The main reasons for the profit decline include increased competition due to the national centralized procurement policy, decreased sales of key products, and rising fixed asset impairment losses and labor costs[6]. - Non-recurring gains and losses are expected to contribute approximately 3.37 million RMB to net profit, primarily from government subsidies and investment income[6]. Delisting Risks - The company warns that if the audited profit figures remain negative, it may face delisting risk as per the Shenzhen Stock Exchange regulations[2][8]. - The projected revenue after deductions is expected to be below 300 million RMB, which could trigger delisting risk warnings[2][8]. Investor Awareness - The company emphasizes the importance of investors being aware of the risks associated with their investments given the current financial outlook[8]. - The company has communicated with its auditing firm regarding the preliminary financial data, and there are no discrepancies reported[5].